Double-strand breaks (DSBs) arise endogenously during normal cellular processes and exogenously by genotoxic agents such as ionizing radiation (IR). DSBs are one of the most severe types of DNA damage, which if left unrepaired are lethal to the cell. Several different DNA repair pathways combat DSBs, with nonhomologous endjoining (NHEJ) being one of the most important in mammalian cells. Competent NHEJ catalyses repair of DSBs by joining together and ligating two free DNA ends of little homology (microhomology) or DNA ends of no homology. The core components of mammalian NHEJ are the catalytic subunit of DNA protein kinase (DNA-PK cs ), Ku subunits Ku70 and Ku80, Artemis, XRCC4 and DNA ligase IV. DNA-PK is a nuclear serine/threonine protein kinase that comprises a catalytic subunit (DNA-PK cs ), with the Ku subunits acting as the regulatory element. It has been proposed that DNA-PK is a molecular sensor for DNA damage that enhances the signal via phosphorylation of many downstream targets. The crucial role of DNA-PK in the repair of DSBs is highlighted by the hypersensitivity of DNA-PK À/À mice to IR and the high levels of unrepaired DSBs after genotoxic insult. Recently, DNA-PK has emerged as a suitable genetic target for molecular therapeutics such as siRNA, antisense and novel inhibitory small molecules. This review encompasses the recent literature regarding the role of DNA-PK in the protection of genomic stability and focuses on how this knowledge has aided the development of specific DNA-PK inhibitors, via both small molecule and directed molecular targeting techniques. This review promotes the inhibition of DNA-PK as a valid approach to enhance the tumor-cell-killing effects of treatments such as IR. The double-strand break (DSB) is generally regarded as the most lethal of all DNA lesions, which if unrepaired severely threatens not only the integrity of the genome but also survival of the organism (Hoeijmakers, 2001; van Gent et al., 2001; Vilenchik and Knudson, 2003) . DSBs can arise endogenously by cellular processes such as cleavage during immunoglobulin gene rearrangement (V(D)J recombination) and meiotic recombination. DSBs are also produced by exposure to ionizing radiation (IR), radiomimetic drugs, such as bleomycin, and the collapse of replication forks when the replication machinery encounters singlestranded breaks (SSBs) (Haber, 2000; Karran, 2000; Norbury and Hickson, 2001; Bassing et al., 2002) . Unrepaired DSBs can activate cell cycle checkpoint arrests and signal for cell death (Jackson, 2001; Norbury and Hickson, 2001) . Possibly even more detrimental to the cell are the unrepaired or misrepaired DSBs that lead to genomic rearrangements which ultimately destabilize the genome, a phenotype observed in a large number of malignancies (Lengauer et al., 1998; Hoeijmakers, 2001; Elliott and Jasin, 2002; Thompson and Schild, 2002; Shiloh, 2003; Vilenchik and Knudson, 2003) . To complicate matters further, the location of the DSBs and the structure of the damaged DNA ends can vary depending on the damaging agent. Thus, DSB ends need to be processed prior to ligation. To combat DSB's intricate nature, complex repair pathways have evolved.
The life of DNA-PK
The double-strand break (DSB) is generally regarded as the most lethal of all DNA lesions, which if unrepaired severely threatens not only the integrity of the genome but also survival of the organism (Hoeijmakers, 2001; van Gent et al., 2001; Vilenchik and Knudson, 2003) . DSBs can arise endogenously by cellular processes such as cleavage during immunoglobulin gene rearrangement (V(D)J recombination) and meiotic recombination. DSBs are also produced by exposure to ionizing radiation (IR), radiomimetic drugs, such as bleomycin, and the collapse of replication forks when the replication machinery encounters singlestranded breaks (SSBs) (Haber, 2000; Karran, 2000; Norbury and Hickson, 2001; Bassing et al., 2002) . Unrepaired DSBs can activate cell cycle checkpoint arrests and signal for cell death (Jackson, 2001; Norbury and Hickson, 2001) . Possibly even more detrimental to the cell are the unrepaired or misrepaired DSBs that lead to genomic rearrangements which ultimately destabilize the genome, a phenotype observed in a large number of malignancies (Lengauer et al., 1998; Hoeijmakers, 2001; Elliott and Jasin, 2002; Thompson and Schild, 2002; Shiloh, 2003; Vilenchik and Knudson, 2003) . To complicate matters further, the location of the DSBs and the structure of the damaged DNA ends can vary depending on the damaging agent. Thus, DSB ends need to be processed prior to ligation. To combat DSB's intricate nature, complex repair pathways have evolved.
Cells have developed three pathways for the repair of DNA DSBs, with the contribution of each varying between lower and higher organisms. Homologous recombination (HR) requires alignment of the broken DNA ends with a homologous region on the sister chromatid (Takata et al., 1998; Haber, 2000; Thompson and Schild, 2002) . This process is mediated by the RAD52 epistasis genes and is the predominant repair pathway during development and the G2 phase of the cell cycle. Singlestrand annealing (SSA) is similar to HR and is dependent upon homologous sequences flanking the break site. The nonhomologous ends are removed and aligned with regions of homology in the complimentary strand. DNA synthesis and ligation completes the process.
Nonhomologous end-joining (NHEJ)
In contrast to HR and SSA, the third pathway, NHEJ repairs the majority of DSBs in G1 and G0 phases of the cell cycle, although a role in other phases of the cell cycle, although minor, does exist Takata et al., 1998; Haber, 2000; Valerie and Povirk, 2003; Burma and Chen, 2004) . The core protein components of NHEJ include the Ku subunits, DNA-PK cs , DNA ligase IV, its cofactor the X-ray cross complementation group 4 protein (XRCC4) and the nuclease Artemis (Chu, 1997; Calsou et al., 1999; Jeggo et al., 1999; Haber, 2000; Karran, 2000; Moshous et al., 2001; Jeggo and O'Neill, 2002) (Figure 1 ). V(D)J recombination, which is required for antibody diversity during immune development, has provided a useful model system for studying NHEJ. The RAG1/ RAG2 proteins introduce DSBs at two adjacent sites, which are generated as hairpin-coding junctions and blunt-ended signal joints. At the break site, the Ku heterodimer binds to the free DNA ends of the DSB, keeping them localized. DNA-PK cs binds the DNAbound Ku to form the DNA-PK complex, which stimulates DNA-PK cs activity through phosphorylation Figure 1 Functions of DNA-PK in NHEJ-mediated repair of DNA DSBs and V(D)J recombination. A DNA DSB break is produced by damage to the genome, for example, by either an endogenous or exogenous damaging species or by a somatic event such as V(D)J recombination (shown inside boxed area). The Ku70/80 heterodimer recognizes and binds the free DNA ends, possibly to prevent nuclease attack. DNA-PK cs is recruited and activated by the Ku complex. Artemis is then recruited to the damage site presumably via a direct interaction with DNA-PK and primes the site of damage with a combination of its endo-and exo-nuclease activities. In V(D)J recombination, Artemis is involved in opening hairpin structures, however, the processing of signal ends is independent of Artemis and DNA-PK. There may also be a role for the Mre11 protein to bind the DNA-PK complex and resect DNA up to the region of microhomology. Next, a DNA polymerase such as pol m is used to synthesize new DNA ends. Finally, the XRCC4/ligase IV complex processes the DNA ends and initiates re-ligation to form a single DNA molecule. The repaired DNA may contain errors such as deletions of the original sequence Life and Death of DNA-PK SJ Collis et al events Chan and LeesMiller, 1996; Dynan and Hoo, 1998; Yoo and Dynan, 1999; Chan et al., 2002) . As well as localizing the DNA ends, this interaction protects them from nuclease digestion prior to ligation in a process called 'synapsis' (DeFazio et al., 2002) . Artemis, which co-associates with DNA-PK cs , cleaves the hairpin junction. Interestingly, both DNA-PK cs and Artemis are redundant for the processing of signal joints. For junctions that require the addition of nucleotides, polymerization then ensues, before recruitment of the XRCC4/Ligase IV complex by DNA-PK to the break site to ligate the DNA breaks together.
Other factors involved in NHEJ
IR-induced DNA damage rarely produces blunt ligatable DNA. In fact, IR produces a wide range of complex breaks and base damage (Ward, 1988) , which can inhibit ligation. These types of breaks require additional processing. Since the 5 0 and 3 0 damaged DNA ends are prone to resection and nucleotide addition, there may be a need for additional components for efficient NHEJ to proceed (reviewed in LeesMiller and Meek, 2003) . The Werner syndrome protein (WRN) is a RecQ like helicase that posseses both ATPdependent helicase activity and 3 0 -5 0 exonuclease activity (Hickson, 2003) . WRN may be required for the removal of 3 0 phosphate or 3 0 phosphoglycolate groups, produced by IR, and it is with interest that WRN cells exhibit a mild IR-sensitive phenotype and that WRN protein is phosphorylated by DNA-PK (Yannone et al., 2001) . Both polynucleotide kinase (PNK) and tyrosyl DNA phosphodiesterase (TDP) also possess the ability to remove 3 0 phosphates and 3 0 phosphoglycolate groups, respectively (Gauss and Lieber, 1996; Mahajan et al., 1999; Mickelsen et al., 1999; Chappell et al., 2002) . The terminal deoxynucleotidyl transferase (TdT) has been shown to add N-nucleotides in a template-independent fashion at the coding ends in V(D)J recombination (Gauss and Lieber, 1996; Mickelsen et al., 1999) . It interacts with Ku and co-localizes with Ku to the sites of damage (Mahajan et al., 1999) . However, it is expressed only in lymphoid cells arguing against a general role in NHEJ.
Artemis is a nuclease with 5 0 -3 0 endonuclease activity that removes 5 0 overhangs and shortens 3 0 overhangs. In vitro phosphorylation of Artemis by DNA-PK activates the hairpin-opening activity of Artemis which is a prerequisite for V(D)J recombination. As yet no proven role for Artemis in the response to IR has been elucidated although Artemis cells display significant radiosensitivity . Finally, there may be a requirement for the Mre11-Rad50-Nbs1 complex (MRN) in NHEJ. Mre11 is also a nuclease with exonuclytic activity similar to Artemis and may therefore process the complex DNA ends before ligation (Huang and Dynan, 2002) . It has also been shown to interact with Ku70 following DNA damage (Goedecke et al., 1999) . Although Nbs1 defective cells show a radiosensitive phenotype attributable to defective DSB repair (Girard et al., 2000) , they are, however, proficient in their ability to undergo V(D)J recombination (Yeo et al., 2000) . Thus, the exact role that the Mre11-Nbs1-Rad50 complex plays in NHEJ is still unclear, although it is undoubtedly an important factor in the repair of DNA DSBs, both through the initial sensing and through functional interactions with both NHEJ and HR factors (Carson et al., 2003; Uziel et al., 2003; Horejsi et al., 2004; Kobayashi et al., 2004; Lee and Paull, 2004) .
To aid in the successful repair of DSBs, it has been suggested that NHEJ requires the action of a DNA polymerase. With this in mind, DNA polymerase m (pol m), a template-dependent polymerase, has been shown to interact with Ku in a manner dependent upon the XRCC4/Ligase IV complex (Mahajan et al., 2002) . Pol m also aids the ligation of complementary ends by the XRCC4/Ligase IV and Ku complexes. Consistent with a role in NHEJ, expression of pol m increases after treatment with agents that produce DSBs and localizes to the break site after damage (Mahajan et al., 2002) .
The role of DNA-dependent protein kinase (DNA-PK) DNA-PK is a nuclear serine/threonine kinase with a molecular mass of B470 kDa. It is comprised of a regulatory subunit, containing the Ku70/80 subunits, and a catalytic subunit, DNA-PK cs (reviewed in Jeggo et al., 1995; Smith and Jackson, 1999) . The amino-acid sequence of the DNA-PK cs suggests that it is a member of the phosphatidylinositol-3-kinase (PI-3-K) superfamily. Unlike the original PI-3-K, DNA-PK cs does not possess lipid kinase activity (Hartley et al., 1995; Smith and Jackson, 1999) . A subfamily of PI-3-Ks with protein kinase activity has been designated PIKKs. Along with DNA-PK cs , other members of this protein family include the ataxia telangectasia mutated protein (ATM) and ataxia telangectasia-related protein (ATR) (Shiloh, 2003; Yang et al., 2003) .
DNA-PK cs protein has a symmetrical crown-shaped top separated from a round bottom, suggesting that the mechanistic function of DNA-PK cs involves internalization of double-stranded DNA (Leuther et al., 1999; Boskovic et al., 2003; Llorca and Pearl, 2004) . Although DNA-PK cs associates with DNA-bound Ku for activation (Chan et al., 2002) , DNA-PK cs can also bind to, and is activated by free DNA ends in the absence of Ku (Hammarsten and Chu, 1998) . Consistent with these data, crosslinking studies of DNA to DNA-PK cs suggest that DNA can activate DNA-PK cs alone Gottlieb and Jackson, 1993) . One of the roles of DNA-PK cs is to protect and align broken ends of DNA alone or as part of a multi-protein complex. But, given its interactions with other proteins of NHEJ as well as non-NHEJ proteins (Table 1) , DNA-PK cs may also act as a scaffold protein to aid the localization of DNA repair proteins to the site of damage. DNA-PK cs, as well as Ku, is found at the ends of chromosomes, suggesting a further role for DNA-PK cs in the maintenance of telomeric stability and the prevention of chromosomal end fusion (d'Adda di Fagagna et al., 2001; Gilley et al., 2001; Cervantes and Lundblad, 2002; de Lange, 2002; Espejel et al., 2002 Espejel et al., , 2004 Rebuzzini et al., 2004) .
Regulation of DNA-PK and phosphorylation of its substrates
The ability of DNA-PK to function in a defined signal transduction damage response pathway has remained suggestive but unproven. DNA-PK cs is autophosphorylated after cellular IR exposures (Chan et al., 2002; Douglas et al., 2002; Ding et al., 2003; Block et al., 2004b; Lou et al., 2004) , which modifies its binding with Ku and has been implicated in the phosphorylation of a wide range of DNA damage/checkpoint proteins. This auto-phosphorylation event is critical for correct NHEJ activity within the cell (Chan et al., 2002; Block et al., 2004b) . Recent work by Lou et al. (2004) has shown that the mediator of DNA damage checkpoint protein 1 (MDC1), which is generally associated with the regulation of both intra S-phase and G2/M phase checkpoints, directly binds to DNA-PK via repeat regions and augments these early auto-phosphorylation events. Thus, these recent data highlight the importance of these early auto-phosphorylation events for efficient NHEJ and indicate how they may be regulated at the molecular level. DNA-PK utilizes an 'S/T-Q' motif, although DNA-PK can also phosphorylate some serine/ threonine residues, which do not constitute this motif (Table 1) (Anderson and Lees-Miller, 1992; Lees-Miller et al., 1992; O'Neill et al., 2000; Douglas et al., 2002) . DNA-PK phosphorylation of Ku and XRCC4 has been reported but has not been linked to any functional changes in NHEJ. DNA-PK phosphorylates Artemis, which changes the function of Artemis, but there is no evidence for in vivo phosphorylation or a direct role in NHEJ .
DNA-PK has also been implicated in phosphorylation of a range of other substrates, but there have been no links to function and to date only in vitro data are available (Table 1 ). There are also many reports of proteins that can regulate DNA-PK activity (Table 2) .
DNA-PK defective cells
The essential role of DNA-PK in protecting genomic stability is highlighted by the phenotypes displayed by DNA-PK-deficient cells. Severe combined immunodeficient (SCID) mice with a defective DNA-PK cs gene Yu et al. (2003) possess a premature aging phenotype and a defective V(D)J recombination phenotype, which results in an accumulation of unprocessed coding intermediates (Bogue et al., 1998) . It has further been suggested that DNA-PK cs -deficient cells and DNA-PK cs À/À mice may also have some defect in signal joint formation (Jhappan et al., 1997; Gao et al., 1998; Taccioli et al., 1998) . It has also been demonstrated that the nonfunctional immune system in SCID mice can lead to the development of thymic T-cell lymphoma (Custer et al., 1985; Jhappan et al., 1997) . Finally, DNA-PK cs -defective SCID mice accumulate large numbers of telomeric fusions consistent with its role in telomere capping (Gilley et al., 2001; Goytisolo et al., 2001) as well as shorter telomeres (Espejel et al., 2002 (Espejel et al., , 2004 . For recent reviews of the role DNA-PK plays in telomere maintenance, please see Bailey et al. (2004a, b) .
As one would expect, given the role of DNA-PK in NHEJ, and similar to other mutants in NHEJ, DNA-PK-deficient cells exhibit a radiosensitive phenotype and are defective in the repair of chromosomal DSBs (reviewed in Smith and Jackson, 1999; Lieber et al., 2003) . A human DNA-PK cs defective glioma cell line M059J has been described ( Lees-Miller et al., 1995) . The radiosensitivity of M059J can be complemented by fusion with murine SCID cells harboring human chromosome 8 (Hoppe et al., 2000) , highlighting the dependence on DNA-PK activity for efficient repair of IR-induced DNA damage.
DNA-PK interactions within the NHEJ machinary
Ku antigen The Ku antigen was first identified as an autoimmune antigen in patients with SclerodermaPolymyositis overlap syndrome (Mimori et al., 1981) . Ku exists as two subunits of B70 and 83 kDa (Ku70 and Ku80 (or Ku86)), with each subunit possessing a leucine zipper motif. Ku binds directly to free DNA termini in a non-sequence-specific manner (Mimori and Hardin, 1986; Blier et al., 1993; Falzon et al., 1993) , which activates DNA-PK cs to form the DNA-PK complex (Yaneva et al., 1997; Calsou et al., 1999; Singleton et al., 1999) . Studies with cells harboring aberrant Ku proteins have indicated that DNA-PK cs binds to the carboxyterminal region of Ku80 (Han et al., 1996a; Muller and Salles, 1997) , which is essential for activation of DNA-PK activity (Gell and Jackson, 1999; Singleton et al., 1999) . DNA-PK cs also phosphorylates Ku70 at serine 6 and Ku80 at serines 577, 580, possibly serine 579, and threonine 715 (Chan et al., 1999) . It has been suggested that Ku possesses ATP-dependent helicase activity and that phosphorylation stimulates this activity (Chu, 1997) , although the crystal structure of the Ku heterodimer showed no obvious helicase domain (Walker et al., 2001; Harris et al., 2004) and, thus, this may not be an important function of Ku in the response to DNA DSBs. It has also been reported that serine 51 of Ku70 is phosphorylated by DNA-PK cs but this event does not affect repair of radiation-induced damage (Jin and Stimulates DNA-PK kinase activity and increases DNA-PK dependent NHEJ Goudelock et al. (2003) Heat shock transcription factor 1 (HSF1)
Possibly stabilizes interaction between DNA-PK and DNA and may regulate DNA-PK after heat stress Peterson et al. (1995) ; Huang et al. (1997) High mobility group proteins 1 and 2 (HMG1 and 2)
Stimulates DNA-PK activity and promotes association of DNA-PK with DNA . Although the regions of Ku that are phosphorylated have been suggested to be important for subunit interactions and DNA binding (Wu and Lieber, 1996) , the binding of Ku to free DNA ends does not appear to be affected by phosphorylation (Boubnov and Weaver, 1995; Chan and Lees-Miller, 1996) .
Artemis One of the genes defective in a subpopulation of human SCID, radio-sensitive (RS-SCID), is the Artemis gene (Moshous et al., 2001) , whose product is found in a stable protein complex with DNA-PK in human cells . Artemis alone appears to be a single-strand-specific nuclease with 5 0 -3 0 exonuclease activity, but upon binding with DNA-PK acquires endonucleolytic activity on 5 0 and 3 0 ends as well as hairpin-opening activity . Artemis-defective cells are radiosensitive and possess a defective V(D)J recombination phenotype consistent with a role for Artemis in opening hairpin coding joints in V(D)J recombination (Moshous et al., 2001; Rooney et al., 2002) . However, Artemis-deficient cells show no gross DSB repair deficiency (Nicolas et al., 1996) , although a DSB repair defect has been proposed (Riballo et al., 2004) . Thus the precise role of Artemis in NHEJ is at present unclear (see Jeggo and O'Neill (2002) 
and references therein).
XRCC4 XRCC4 is also phosphorylated in response to IR (Matsumoto et al., 2000) . This phosphorylation is defective in DNA-PK-deficient cells, suggesting that XRCC4 is a target of DNA-PK (Critchlow et al., 1997; Matsumoto et al., 2000) . Several studies have tried to resolve the physiological role of XRCC4 phosphorylation. DNA-PK has been shown to phosphorylate serine 53 of XRCC4, but this event is dispensable for proficient V(D)J recombination (Mizuta et al., 1997) . Yu et al. (2003) identified XRCC4 serines 260 and 318 as major sites of DNA-PK phosphorylation and possibly serines 193, 259, 302, 313, 325 and 326 as well as threonine 321 as minor sites. However, an XRCC4 mutant with all nine DNA-PK phosphorylation sites mutated showed the same sensitivity to IR as those expressing the wildtype DNA-PK protein. Leber et al. (1998) showed that XRCC4 also undergoes tyrosine phosphoryation, suggesting that XRCC4 may be regulated by other kinases in addition to DNA-PK. Phosphorylation of XRCC4 appears to prevent its binding to DNA (Modesti et al., 1999) , but does not effect its binding to DNA Ligase IV, suggesting that one function of XRCC4 phosphorylation is to dissociate the XRCC4/Ligase IV from DNA, possibly after repair of the break site.
The death of DNA-PK
Since the identification and cloning of the components of DNA-PK, its importance in the maintenance of genome integrity has been realized through the efforts of many different research groups. DNA-PK may also play a vital role in cellular responses to low amounts of radiation-induced damage (Vaganay-Juery et al., 2000; Marples et al., 2002) , which make it an attractive molecular target. This is especially true given that several studies have reported that components of the DNA-PK complex are upregulated in cancer cells (Sirzen et al., 1999; Wilson et al., 2000; Zhao et al., 2000; Shintani et al., 2003) . Radiation remains a highly effective means to target human tumor-specific death. The potential for DNA-PK inhibitors to enhance the efficacy of radiotherapy without effecting normal cell growth is strong (Figure 2) .
Small-molecule inhibitors of DNA-PK
Classical inhibitors The fact that DNA-PK kinase activity is essential for its function in both DNA DSB repair and V(D)J recombination (Kurimasa et al., 1999; Beamish et al., 2000; Kienker et al., 2000) opens the door for the development of drugs that can specifically inhibit this vital kinase activity. Initial reports described small-molecule inhibition of DNA-PK using two nonselective PI-3 kinase inhibitors: wortmannin and LY294002. Both chemicals inhibit ATP binding within the catalytic site of DNA-PK cs albeit through slightly different modes of action (Arcaro and Wymann, 1993; Vlahos et al., 1994; Ui et al., 1995; Gu et al., 1996; Rosenzweig et al., 1997; Sarkaria et al., 1998; Izzard et al., 1999) .
Wortmannin is a noncompetitive, general inhibitor of PI-3 kinases with an IC 50 in the nanomolar range for DNA-PK cs (see Stein (2001) and references therein). Inhibition of DNA-PK by wortmannin involves the irreversible alkylation of lysine 802, which resides in the active site and is critical for the phosphate transfer reaction (Wymann et al., 1996) . Wortmannin is an effective radiosensitizer of a variety of normal and cancer cells, via its ability to render DNA-PK incapable of performing DNA repair functions following radiation exposure (Price and Youmell, 1996; Gu et al., 1996; Rosenzweig et al., 1997; Sarkaria et al., 1998; Chernikova et al., 1999; Izzard et al., 1999; Boulton et al., 2000; DiBiase et al., 2000; Hashimoto et al., 2003) . Wortmannin has been reported to produce a dose-reduction factor (DRF; the factor by which the dose of radiation can be reduced in the presence of the sensitizing agent to achieve the same level of cell killing in the absence of the sensitizing agent) for IR at 10% survival of between 1.4 and 3.0 from a variety of laboratories (Price and Youmell, 1996; Rosenzweig et al., 1997; Sarkaria et al., 1998; Chernikova et al., 1999; Boulton et al., 2000; DiBiase et al., 2000; Collis et al., 2003b) . However, despite all these encouraging studies, undesirable properties of wortmannin, such as its insolubility in aqueous solutions and in vivo toxicity, have forced the development of more clinically translatable compounds.
LY294002 is a structurally unrelated compound that is also a nonselective competitive inhibitor of PI-3 kinases, with an IC 50 of B1.4 mM for DNA-PK cs (Vlahos et al., 1994; Izzard et al., 1999; Stein, 2001 ). LY294002 has been reported to produce a DRF for IR at 10% survival of between 1.5 and 1.8 (Rosenzweig et al., 1997; Gupta et al., 2001) . These results are encouraging for the potential antitumor activity of future similar compounds. Due to its inhibition of the Ras signaling pathway, LY294002 has also been assessed for antitumor effects in vivo (see McKenna and Muschel (2003) and references therein). These studies have aimed to assess the effectiveness of LY294002 both as a monotherapy and in combination with radiation (Hu et al., 2000; Edwards et al., 2002; Semba et al., 2002; Gupta et al., 2003) . Although these in vivo studies demonstrate the potential of LY294002 as a radiosensitizing agent, its relative instability, quick metabolic clearance (B1 h (Gupta et al., 2003) ) and in vivo toxicity make its clinical evaluation in humans unfeasible. However, the basic chemical structure of LY294002 has offered a lead compound upon which more potent novel inhibitors can be developed that possess more desirable properties to aid their future assessment.
The new breed of DNA-PK inhibitors Stockley et al. (2001) described the in-depth synthesis of a previously reported selective DNA-PK inhibitor named OK-1035 (Take et al., 1995) . In vitro, OK-1035 is capable of Figure 2 Inhibition of DNA-PK by small-molecule inhibitors and/or molecular targeting strategies. Shown is a schematic representation of DNA-PK production from gene to protein and inhibition of these processes by either small-molecule inhibitors or molecular targeting strategies such as antisense, siRNA, inhibitory peptide/proteins and antibody fragments. Antisense and siRNA species inhibit the production of protein by causing degradation of the mRNA (by different mechanisms), leading to decreased levels of DNA-PK within the cell. Antisense (and possibly siRNA) can also sterically hinder ribosome-mediated translation. Small-molecule inhibitors and inhibitory peptides/proteins and antibody fragments inhibit DNA-PK function by binding to specific regions of the protein complex. Ultimately, such inhibition prevents either the formation of the DNA-PK trimer, or an impaired DNA-PK molecule, which is inefficient at repairing DNA DSBs, ultimately resulting in increased chromosomal abnormalities and eventual mitotic cell death Life and Death of DNA-PK SJ Collis et al inhibiting DNA-PK; however, the IC 50 of 100 mM is physiologically high and unlikely to be useful for in vivo studies. One of the first groups of novel LY294002-based compounds designed to show increased sensitivity for DNA-PK cs were reported recently by Hollick et al. (2003) . NU7026 demonstrated the most potent activity with 70-fold more selectivity for DNA-PK cs compared to other PI-3 kinases. Importantly, NU7026 was over five-fold more selective for DNA-PK cs than for ATM and ATR. A recent study showed that NU7062 resulted in DRFs of B1.5 at 10% IR survival of mouse embryonic fibroblasts (Veuger et al., 2003) .
As an alternative to the identification of novel DNA-PK inhibitors via the mass screening of chemically synthesized compounds, naturally occurring compounds derived from certain species of vanilla pods were recently shown to be effective inhibitors of DNA-PK cs (Durant and Karran, 2003) . Durant and Karran reported that vanillin could inhibit DNA-PK activity (likely via interaction with specific lysine residues in the active site) in cell-free assays. This inhibition was also shown to be specific to NHEJ and selective for DNA-PK cs over ATM and ATR (Durant and Karran, 2003) . At nontoxic concentrations of vanillin, a DRF of B1.3 was achieved at 10% cell survival following radiation of human ovarian carcinoma cells. Similar to the combined effects of DNA-PK and PARP inhibitors reported by Veuger et al. (2003) , Durant and Karran (2003) demonstrated that the presence of nontoxic concentrations of vanillins augmented the cytotoxic effects of cisplatin. Ismail et al. (2003) recently reported the development of a chemically synthesized inhibitor of DNA-PK cs , SU11752, that competitively inhibited DNA-PK cs (via binding of ATP), resulting in less efficient repair of DNA DSBs. Moreover, this activity was selective for DNA-PK cs over other PI-3 kinases. Pretreatment of human glioblastoma cells with 50 mM SU11752 led to a DRF of B3.0 at 10% IR survival.
Molecular targeting of DNA-PK
Antisense and siRNA strategies Marangoni et al. (2000b) used a full-length inverted cDNA to target Ku80 in human fibroblast cell lines. This resulted in a DRF at 10% IR survival of B1.7 for stable cell lines expressing the Ku80 antisense compared to control cell lines, which was likely a consequence of reduced DNA end-binding capacity and DSB repair rates observed in these cells. Belenkov et al. used the human glioma cell line pair M059K and M059J (respectively, proficient and deficient in DNA-PK activity) to demonstrate the effectiveness of transiently transfected naked antisense oligonucleotides that targeted many different regions of Ku80 mRNA (Belenkov et al., 2002) . The most effective antisense caused an enhanced radiosensitivity with a DRF of B2 at 10% survival in the M059K cells, which was not apparent in the M059J cells (DRF ¼ 1.0). The Ku70 subunit has also been recently targeted both in vitro and in vivo by antisense molecules in two independent studies (Omori et al., 2002; Li et al., 2003a) . The cells expressing the antisense molecule were more sensitive to IR and several DNA-damaging agents (bleomycin, cisplatin and MMS) compared to parental control cells (Omori et al., 2002) . Li et al. (2003a) used a heatrestricted (via the hsp70 promoter) replication-defective adenovirus to control the expression of a Ku70 antisense molecule exogenously delivered to cultured mouse tumor cells and xenografts. In vitro studies demonstrated an B80% reduction in Ku70 protein expression upon heat shock that gave rise to a DRF of B1.5 at 10% IR survival. Similar results were obtained in vivo (DRF of B1.3 at 10% IR survival) with a significant growth delay observed (up to 6 days) in tumors treated with virus/heat shock and radiation compared to appropriate control groups. These in vivo data reported by Li and colleagues highlight the feasibility of exogenous delivery of molecular targeting gene therapies to augment the tumor cellkilling effects of IR.
As well as targeting the Ku subunits of DNA-PK to enhance radiosensitivity, the catalytic subunit, DNA-PK cs , has also been targeted for potential radio-gene therapy regimes. Recently, antisense oligonucleotides have been used to target three separate regions of the mRNA in order to downregulate DNA-PK cs in several human tumor cell lines (Sak et al., 2002) . Specific inhibition of DNA-PK cs activity via treatment of high doses of naked antisense RNA targeting the AUG translation initiation region of the mRNA led to deficient DNA DSB repair following 30 Gy IR exposure, which was comparable to pretreatment of cells with 5-10 mM of wortmannin.
Recently, siRNA-based approaches have been employed to specifically target DNA-PK cs (Peng et al., 2002; Collis et al., 2003b) . Peng et al. used consecutive transfection of normal fibroblasts with naked RNA targeted to two different regions of the mRNA sequence. They demonstrated that DNA-PK cs protein expression was reduced by B80-90%, which caused an increase in sensitivity to radiation (DRF B2.0 at 10% survival), chromosomal aberrations and mutation frequency (Peng et al., 2002) . We independently used a plasmid-based approach to deliver siRNAs targeted to three different regions of the DNA-PK cs mRNA sequence (Collis et al., 2003b) and obtained the same level of reduced protein expression (B80-90%) and significantly enhanced radiosensitivity (DRF B1.5 at 20% survival).
Inhibitory antibody and peptide/protein-mediated inhibition Several groups have demonstrated that inhibition of DNA-PK can also be achieved by the exogenous delivery of inhibitory peptides, dominantnegative forms of the protein or inhibitory antibody fragments (Marangoni et al., 2000a; Kim et al., 2002; Li et al., 2003b) .
Stable Chinese hamster ovary cell lines expressing a 32 kDa portion of the C-terminal region (representing amino acids 449-732) of Ku80 have been constructed, which had dominant-negative effects on normal DNA-PK function, presumably by abrogating Ku binding to DNA-PK cs , and inhibited the heterodimer's ability to bind DNA breaks (Marangoni et al., 2000a) . These stable cell lines were sensitive to IR, with a DRF at 10% survival of B2.0 compared to control cell lines. They were also unable to successfully repair DNA DSBs (Marangoni et al., 2000a) . Kim et al. (2002) synthesized a dominant-negative peptide representing amino acids 720-732 of Ku80, (encompassing the same region used by Marangoni et al.) to inhibit DNA-PK activity following transfection into human breast cancer cell lines. As with the dominant-negative Ku80 protein fragment, this peptide was shown to reduce DNA-PK cs kinase activity, ultimately leading to inefficient recognition of DNA DSBs. These cells had increased sensitivity to radiation using growth inhibition assays. Li et al. (2003b) have demonstrated inhibition of DNA-PK cs function by use of a single-chain variable antibody fragment. Unlike the small-molecule inhibitors described above that target the active site of DNA-PK cs , this antibody fragment bound to a regulatory region that is unique to DNA-PK cs (not present in ATM or ATR). Although exogenous delivery of the antibody fragment did not drastically abrogate the kinase activity of DNA-PK, it did lead to inhibition of NHEJ in human skin melanoma cell line following low levels of radiation exposure (Li et al., 2003b) .
Finally, it is worth mentioning that certain viruses may have evolved methods to inhibit DNA repair mechanisms as a means to increase viral infection. Exogenous delivery of genes encoding these proteins or peptides may yield other means by which DNA-PK activity could be abrogated in tumors prior to treatment with DNAdamaging agents. Examples of such proteins are the herpes simplex virus type (HSV-1) ICP0 and adenovirus serotype 5 (Ad5) E4-34k. The immediate early gene product ICP0 (also known as Vmw110) of HSV-1 has been shown to bind DNA-PK cs and promote its rapid ubiquitin-mediated degradation Parkinson et al., 1999) . Exogenous expression of this protein increases sensitivity to radiation in prostate cancer cells (Collis et al., unpublished data) . In addition to HSV-1 ICP0, the Ad5 gene product E4-34k has been shown to bind DNA-PK cs and inhibit V(D)J recombination (Boyer et al., 1999) . This may increase viral replication and prevent the linear double-stranded viral genome from being 'repaired' by the host cell DSB repair machinery. However, we have recently shown that exogenous expression of E4-34k alone does not confer a radiosensitive phenotype in several human tumor cell lines (Collis et al., 2003a) . Stracker et al. (2002) demonstrated that E4-34k when bound to additional Ad5 gene products E1B-55k or E4-11k, or the E4-11k protein on its own, could lead to respective degradation and mis-localization of components of the Mre11-Nbs1-Rad50 complex (Carson et al., 2003) . These data may help explain the synergistic effects of some oncolytic adenoviruses when used in combination with IR , and may offer an alternative strategy for the development of potential radio-gene therapy regimes.
Concluding remarks
The more knowledge we gather regarding the life of DNA-PK, the better armed we are to plan and successfully bring about its death. Recently, our understanding of the role DNA-PK plays in NHEJ processes and how its activity is regulated within the cell, as well as improvement in the development of specific inhibition strategies, has increased. Inhibition of DNA-PK as a strategy for increased tumor cell killing has progressed, but there are numerous challenges that lay ahead in the development of effective radio-gene and other adjuvant gene therapy approaches. For small-molecule inhibitors, improved specificity and concomitant reduction in toxicity must be addressed if such compounds are to find their way from the bench to the bedside. For molecular targeted approaches, improvements in vector development will continue to be critical in establishing less immunogenic viruses/liposomes with the capacity to carry larger transgenes. Modification of the surface fibers of viruses will hopefully yield improved delivery and more specific targeting of the tumor cells. The increasing knowledge of human genetic information may give rise to new tumor-and/or cell-specific promoters to limit the expression of the types of molecular therapeutics. If these challenges can be met, then their combined use with further advancements such as improvements in conformal radiotherapy regimes could provide significantly enhanced local control of tumors and prevention of metastatic disease in many different types of malignancies.
